Strategic Partnerships Synexa has a history of strategic collaborations and acquisitions (Waters collaboration, Alderley Analytical acquisition, Parexel partnership, CEPI membership). This presents opportunities to position cross-selling of advanced biomarker and bioanalytical services to organizations seeking integrated lab capabilities and broader service scopes.

Global Lab Footprint Operating across Manchester, Cape Town, and Turku with over 200 staff, Synexa can support multicenter, global clinical trials and harmonized analytics. This enables selling into sponsors requiring geographically diverse sample analysis and centralized data comparability.

Advanced Analytics Core expertise in biomarker development, LC-MS/MS, ELISA, RIA, flow cytometry, ELISpot, and genetic services positions Synexa to target sponsors needing complex, turnkey assay development and translational studies, including immuno-oncology, infectious disease, and PK/PD programs.

Sustainability Focus Recent Green Lab Certification and sustainability initiatives signal a commitment to eco-friendly operations. This can be leveraged to win business with ESG-conscious sponsors and to differentiate in bids that emphasize responsible lab practices.

Financial Anonymity to Growth With revenue in the 10–25 million range and a growing service portfolio through acquisitions and new technology trials (Xevo TQ Absolute XR trial), there are opportunities to target mid-market biotechnology firms expanding their biomarker programs and seeking scalable CRO partnerships.